| Treatment | Mechanism of Action | Dosing Protocol | Timing/Window | Clinical Status | Key Evidence |
|---|---|---|---|---|---|
| N-acetylcysteine (NAC), IV traditional 3-bag | Replenishes cysteine for hepatic glutathione synthesis; supports detoxification of NAPQI; also scavenges mitochondrial oxidants/peroxynitrite and supports bioenergetics | 150 mg/kg over 15 min to 1 h, then 50 mg/kg over 4 h, then 100 mg/kg over 16 h (total 300 mg/kg over ~20.25–21 h) | Most effective when started within 8–10 h of overdose; may be extended or intensified in massive ingestion, delayed presentation, or persistent toxicity | Standard of care; approved/established antidote | (pqac-00000017, pqac-00000018, pqac-00000019, pqac-00000023) |
| N-acetylcysteine (NAC), IV 2-bag | Same core mechanism as above, with simplified infusion design intended to reduce adverse reactions and streamline delivery | 200 mg/kg over 4 h, then 100 mg/kg over 16 h | Early treatment preferred; considered an alternative simplified IV regimen | Established clinical alternative in some protocols | (pqac-00000018, pqac-00000019) |
| N-acetylcysteine (NAC), IV SNAP-style regimen | Same antidotal mechanism; shorter regimen designed to reduce adverse drug reactions while preserving efficacy | 300 mg/kg over 12 h | Early treatment; may support treatment intensification strategies in very large overdoses | Implemented/clinically studied protocol variation | (pqac-00000017, pqac-00000018, pqac-00000021) |
| N-acetylcysteine (NAC), oral 72-hour regimen | Replenishes glutathione precursors and limits progression of NAPQI-mediated injury | 140 mg/kg loading dose, then 70 mg/kg every 4 h for 17 doses (total 72 h) | Highly effective when begun early; still used where oral therapy is feasible | Established/legacy standard regimen | (pqac-00000018, pqac-00000019, pqac-00000023) |
| Fomepizole (4-methylpyrazole) | Inhibits CYP2E1-mediated NAPQI formation; also inhibits JNK activation, offering mechanistically distinct protection from NAC | No universally established APAP-specific standard dose from retrieved evidence; used as adjunct with NAC in selected high-risk cases | Considered especially for massive ingestion, delayed presentation, renal injury, or patients above high-risk nomogram lines | Experimental/adjunctive; promising but not standard universal care | (pqac-00000016, pqac-00000017, pqac-00000020, pqac-00000022) |
| Activated charcoal | Gastrointestinal decontamination to reduce acetaminophen absorption from the gut | Standard toxicology use after recent ingestion; exact dosing not provided in retrieved evidence | Best soon after ingestion, before full absorption | Established supportive intervention in overdose management | (pqac-00000021) |
| Liver transplantation | Replaces failed liver in patients progressing to acute liver failure despite antidotal/supportive care | No dose; candidacy generally based on prognostic criteria such as King's College Criteria | Reserved for fulminant hepatic failure / poor prognosis cases, often late presenters or nonresponders | Established rescue therapy | (pqac-00000022, pqac-00000010, pqac-00000013) |
| Calmangafodipir | Superoxide dismutase mimetic targeting mitochondrial oxidant stress | Investigational; specific dosing not provided in retrieved evidence | Intended for patients at risk of ongoing mitochondrial injury despite NAC | Experimental / clinical investigation | (pqac-00000016, pqac-00000021, pqac-00000022) |
| PEG-TPO (thrombopoietin mimetic peptide) | Promotes liver recovery/regeneration in late injury settings when NAC is less effective | Experimental; specific dosing not provided in retrieved evidence | Proposed benefit around ~24 h after overdose in preclinical work | Experimental / preclinical | (pqac-00000016) |
| Wharton's Jelly mesenchymal stem cells (MSCs) | Reported to protect mitochondrial function and support hepatic repair/regeneration | Experimental cell therapy; dosing not provided in retrieved evidence | Investigational, likely for delayed/severe injury rather than early detoxification | Experimental / preclinical | (pqac-00000016) |


*Table: This table summarizes established and emerging treatments for acetaminophen hepatotoxicity, including mechanisms, dosing frameworks, treatment windows, and evidence status. It is useful for comparing standard antidotal care with adjunctive and experimental strategies.*